SCHEMBL26965604

SCHEMBL26965604

CC(C)(C)OC(=O)NC(C)(C(=O)O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.40
CYP2C19 P33261 1/20 0.40
S1PR3 Q99500 1/20 0.38
AAK1 Q2M2I8 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
TSHR P16473 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CTSL P07711 1/20 0.37
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
IDO1 P14902 2/20 0.36
POLB P06746 1/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26965593 0.88 HTT (0.43) CYP2C19S1PR3AAK1MRGPRX4CTSL
SCHEMBL27159043 0.87 GAA (0.44) CYP2C19CTSLGAASMN1; SMN2POLB
SCHEMBL3946429 0.87 GAA (0.44) CYP2C19CTSLGAASMN1; SMN2POLB
SCHEMBL7416176 0.84 BCL2 (0.43) GAAKDM4ESMN1; SMN2POLB
SCHEMBL4440995 0.84 BCL2 (0.43) GAAKDM4ESMN1; SMN2POLB
SCHEMBL25402601 0.82 CTSL (0.48) S1PR3CTSLGAAKDM4EIDO1
SCHEMBL27159397 0.79 PPARA (0.41) TSHRCTSLGAAPPARGPPARA
SCHEMBL27159394 0.79 PPARA (0.41) TSHRCTSLGAAPPARGPPARA
SCHEMBL4221670 0.79 MIF (0.47) TSHRCTSLGAAPPARACA12
SCHEMBL19331927 0.79 MIF (0.47) TSHRCTSLGAAPPARACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11945811-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2024-04-02 US disclosed
CN-117561247-A Novel potassium channel inhibitors 阿塞西翁制药公司 2024-02-13 CN disclosed
EP-4313973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2024-02-07 EP disclosed
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2023-12-21 US disclosed
WO-2022200162-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACECION PHARMA APS (DK) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945811-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 SSTR4 2553/4885CYP2C19 1480/4885S1PR3 1143/4885
US-20230406845-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 SSTR4 3008/4885CYP2C19 1628/4885S1PR3 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.